178 related articles for article (PubMed ID: 18753472)
1. How important is surrogate consent for stroke research?
Flaherty ML; Karlawish J; Khoury JC; Kleindorfer D; Woo D; Broderick JP
Neurology; 2008 Nov; 71(20):1566-71. PubMed ID: 18753472
[TBL] [Abstract][Full Text] [Related]
2. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
3. [Prospects of thrombolytic therapy for acute ischemic stroke].
Nakashima T; Minematsu K
Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
[TBL] [Abstract][Full Text] [Related]
4. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
[TBL] [Abstract][Full Text] [Related]
5. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
[TBL] [Abstract][Full Text] [Related]
6. The impact of lesion side on acute stroke treatment.
Di Legge S; Fang J; Saposnik G; Hachinski V
Neurology; 2005 Jul; 65(1):81-6. PubMed ID: 16009890
[TBL] [Abstract][Full Text] [Related]
7. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
[TBL] [Abstract][Full Text] [Related]
8. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
[TBL] [Abstract][Full Text] [Related]
9. Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.
Bruno A; Saha C; Williams LS
J Stroke Cerebrovasc Dis; 2009 Jan; 18(1):56-9. PubMed ID: 19110146
[TBL] [Abstract][Full Text] [Related]
10. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study.
Krumholz HM; Gross CP; Peterson ED; Barron HV; Radford MJ; Parsons LS; Every NR
Am Heart J; 2003 Nov; 146(5):839-47. PubMed ID: 14597933
[TBL] [Abstract][Full Text] [Related]
11. A graphic reanalysis of the NINDS Trial.
Hoffman JR; Schriger DL
Ann Emerg Med; 2009 Sep; 54(3):329-36, 336.e1-35. PubMed ID: 19464756
[TBL] [Abstract][Full Text] [Related]
12. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
[TBL] [Abstract][Full Text] [Related]
13. Thrombolysis 2004: the good, the bad, and the ugly.
Caplan LR
Rev Neurol Dis; 2004; 1(1):16-26. PubMed ID: 16397447
[TBL] [Abstract][Full Text] [Related]
14. [Alteplase treatment for acute stroke 2007: an effective therapeutic option at our disposal].
Carneado-Ruiz J; Saver JL
Rev Neurol; 2007 Jul 1-15; 45(1):42-52. PubMed ID: 17620265
[TBL] [Abstract][Full Text] [Related]
15. IV t-PA therapy in acute stroke patients with atrial fibrillation.
Kimura K; Iguchi Y; Shibazaki K; Iwanaga T; Yamashita S; Aoki J
J Neurol Sci; 2009 Jan; 276(1-2):6-8. PubMed ID: 19010485
[TBL] [Abstract][Full Text] [Related]
16. Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
Charipar R; Charipar E
WMJ; 2008 Jul; 107(4):176-80. PubMed ID: 18702433
[TBL] [Abstract][Full Text] [Related]
17. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research.
Lu M; Lyden PD; Brott TG; Hamilton S; Broderick JP; Grotta JC
J Neurosci Methods; 2005 Apr; 143(2):209-16. PubMed ID: 15814153
[TBL] [Abstract][Full Text] [Related]
18. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
Wang Y; Wu D; Zhao X; Ma R; Guo X; Wang C; Liu L; Zhao W; Wang Y
Surg Neurol; 2009 Aug; 72 Suppl 1():S2-7. PubMed ID: 18423545
[TBL] [Abstract][Full Text] [Related]
19. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry.
Deng YZ; Reeves MJ; Jacobs BS; Birbeck GL; Kothari RU; Hickenbottom SL; Mullard AJ; Wehner S; Maddox K; Majid A;
Neurology; 2006 Feb; 66(3):306-12. PubMed ID: 16476927
[TBL] [Abstract][Full Text] [Related]
20. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Hacke W; Donnan G; Fieschi C; Kaste M; von Kummer R; Broderick JP; Brott T; Frankel M; Grotta JC; Haley EC; Kwiatkowski T; Levine SR; Lewandowski C; Lu M; Lyden P; Marler JR; Patel S; Tilley BC; Albers G; Bluhmki E; Wilhelm M; Hamilton S; ; ;
Lancet; 2004 Mar; 363(9411):768-74. PubMed ID: 15016487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
